Latest News

The July edition of the FH Europe e-Flash rounds up the latest news In this edition: FH Europe representatives meet EAS FHSC at the EAS Congress in Maastricht and a link to news from the Congress EU news on endocrine disruptors Rare disease and research updates Do we need taxes to ensure we eat healthily? […]

The Spring edition of the FH Europe e-Flash rounds up the latest news Stories include: FH Europe and European Atherosclerosis Society agree closer cooperation to improve treatment and research for FH 87th EAS Congress in Maastricht News about Rare Disease Day 2019 News from the network from Austria, Germany, Ireland, Malta, Spain and UK Use […]

The European Atherosclerosis Society FH Studies Collaboration and FH Europe announce partnership We are delighted to announce to a new collaboration between Familial Hypercholesterolaemia (FH) patient representative network, FH Europe, and the FH investigators from all over the world who work together as part of the EAS FH Studies Collaboration (FHSC). This announcement is made […]

The December edition of the FH Europe e-Flash rounds up the latest news Stories include: FH Europe Third Annual Network Meeting – Paris, November 2018 New members’ area on FH Europe website launched News of FH Foundation Global Summit FH Global Call to Action discussions at WHF Dubai Congress News from the network Austria, Finland, […]

At FH Europe’s annual meeting in Paris in November 2018, members were moved by the awareness-raising video that Anhet, the French FH patient association, produced. English sub-titles were added to the video which you can view below:

The October edition of the FH Europe e-Flash rounds up the latest news Stories include: FH Awareness Day on 24 September – EAS special ‘FH’ edition of its journal FH Sweden has aligned with the Swedish Hart and Lung Association Latvia’s separate disease code for FH is approved effective 1st October 2018 FH Awareness day […]
FH Europe is supported by an educational grant from Amgen Limited, Sanofi, Akcea Therapeutics Inc. and Amryt